AstraZeneca (LON:AZN) Stock Keeps Buy Rating at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a note issued to investors on Tuesday, Digital Look reports. They presently have a £175 price objective on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 40.00% from the stock’s current price.

AZN has been the topic of several other research reports. Berenberg Bank reaffirmed a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, October 7th. Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price target on shares of AstraZeneca in a research report on Tuesday, September 8th. Citigroup lifted their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £117 price objective on shares of AstraZeneca in a report on Tuesday, September 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of £153.57.

AstraZeneca Price Performance

AstraZeneca stock opened at £125 on Tuesday. AstraZeneca has a 52 week low of £114.04 and a 52 week high of £157.32. The business has a 50-day simple moving average of £121.01 and a 200 day simple moving average of £131.12. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The stock has a market cap of £193.86 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 0.86 and a beta of 0.20.

Insider Activity

In other news, insider Michel Demare purchased 2,500 shares of the business’s stock in a transaction on Monday, September 14th. The shares were acquired at an average price of £121.21 per share, with a total value of £303,025. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.